Treatment comparisons and changes between baseline and treatment endpoint for secondary outcomes
| Secondary outcome | Changes between baseline and endpoint* | Treatment comparisons† | |||||
|---|---|---|---|---|---|---|---|
| Sildenafil prn | Tadalafil OaD | Tadalafil prn | Tadalafil OaD–sildenafil prn | Tadalafil OaD–tadalafil prn | Tadalafil prn–sildenafil prn | ||
| SEAR scale | 25.40 (1.36) | 25.56 (1.36) | 26.92 (1.35) | 0.23 (1.11) | −1.47 (1.11) | 1.71 (1.10) | |
| n=347 | n=348 | n=355 | [–1.95 to 2.42; P=0.834] | [−3.65 to 0.70; P=0.185] | [−0.46 to 3.87; P=0.123] | ||
| Sexual relationship | 19.50 (1.31) | 19.40 (1.31) | 20.42 (1.30) | –0.07 (1.07) | −1.12 (1.06) | 1.06 (1.06) | |
| n=347 | n=349 | n=355 | [−2.17 to 2.04; P=0.951] | [−3.22 to 0.97; P=0.291] | [−1.03 to 3.15; P=0.320] | ||
| Confidence total | 22.87 (1.29) | 22.94 (1.29) | 24.13 (1.29) | 0.11 (1.050) | −1.30 (1.040) | 1.42 (1.04) | |
| n=347 | n=348 | n=355 | [−1.95 to 2.17; P=0.915] | [−3.35 to 0.74; P=0.212] | [−0.63 to 3.46; P=0.174] | ||
| IIEF-EF domain score | 9.70 (0.36) | 8.68 (0.36) | 9.54 (0.36) | −0.85 (0.30) | −0.80 (0.29) | −0.05 (0.29) | |
| n=348 | n=350 | n=355 | [−1.43 to −0.27; P=0.004] | [−1.37 to −0.22; P=0.007] | [−0.62 to 0.53; P=0.866] | ||
| EDITS score | 75.68 (1.32) | 75.81 (1.31) | 79.50 (1.31) | 0.12 (1.28) | −3.55 (1.27) | 3.66 (1.27) | |
| n=348 | n=351 | n=355 | [−2.40 to 2.64; P=0.926] | [−6.05 to −1.04; P=0.006] | [1.16 to 6.17; P=0.004] | ||
| Morning erection frequency | 0.11 (0.02) | 0.26 (0.02) | 0.20 (0.02) | 0.15 (0.01) | 0.06 (0.01) | 0.09 (0.01) | |
| n=347 | n=352 | n=355 | [0.12 to 0.18; P<0.001] | [0.03 to 0.09; P<0.001] | [0.06 to 0.12; P<0.001] | ||
EDITS=Erectile Dysfunction Inventory of Treatment Satisfaction; IIEF-EF=International Index of Erectile Function-Erectile Function Domain; prn=as required; OaD=once a day; SEAR=Self-Esteem and Relationship.
* Mean (standard error).
† Least square mean difference (standard error) [95% confidence interval; P value].